Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Botto, G.L.
Right arrow Articles by Sagone, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Botto, G.L.
Right arrow Articles by Sagone, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Atrial fibrillation: the remodelling phenomenon

G.L. Botto*, M. Luzi and A. Sagone

Department of Cardiology, St Anna Hospital, Como, Italy

* Giovanni Luca Botto, MD, FESC, Divisione di Cardiologia, Ospedale ‘Sant’ Anna', Via Napoleona 60, 22100, Como, Italy

Abstract

Atrial fibrillation (AF) is a progressive disease and may be self-sustaining. The processes that lead to the worsening of AF over time include electrical, contractile, neurohormonal, macroanatomical and ultrastructural changes, and these may occur over different periods of time. The term ‘electrical remodelling’ indicates long-term changes in atrial electrophysiological parameters that result from prolonged changes in atrial rate. The mechanism of tachycardia-induced remodelling is associated with altered ion channel function, the most important of which is a reduction in L-type calcium current, which is responsible for a reduction in the duration of the action potential, atrial refractory period and refractory period adaptation to rate. Recovery from atrial electrical remodelling occurs within a few days, even in cases of very long-lasting AF, although clinically the atria remain vulnerable for weeks after cardioversion. A so-called ‘second factor’ may play a role in this prolonged vulnerability to recurrent AF. In animals tachycardia-induced electrophysiological modification is reduced by verapamil and angiotensin II receptor antagonists, but the effect of these drugs in preventing atrial electrical remodelling in humans is disputed. Despite these findings, there is growing clinical evidence that verapamil and angiotensin II receptor antagonists could reduce the recurrence of AF after cardioversion. In this report current knowledge of the mechanisms and clinical consequences of AF-induced electrical remodelling is discussed.

Key Words: Antiarrhythmic drugs • Atrial fibrillation • Atrial remodelling • Cardioversion of atrial fibrillation • Electrophysiological remodelling


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
M.S. Kostapanos, E.N. Liberopoulos, J.A. Goudevenos, D.P. Mikhailidis, and M.S. Elisaf
Do statins have an antiarrhythmic activity?
Cardiovasc Res, July 1, 2007; 75(1): 10 - 20.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.